Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV

Lancet HIV. 2021 Jun;8(6):e317-e318. doi: 10.1016/S2352-3018(21)00099-0.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenine / analogs & derivatives
  • Adenine / therapeutic use
  • Adult
  • Alanine
  • Amides
  • Antiretroviral Therapy, Highly Active / methods
  • BNT162 Vaccine
  • CD4 Lymphocyte Count
  • CD4-CD8 Ratio
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / pathology*
  • CD4-Positive T-Lymphocytes / virology
  • CD8-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / pathology*
  • CD8-Positive T-Lymphocytes / virology
  • COVID-19 / immunology
  • COVID-19 / prevention & control
  • COVID-19 / virology
  • COVID-19 Vaccines / administration & dosage*
  • Emtricitabine / therapeutic use
  • HIV Infections / drug therapy
  • HIV Infections / immunology
  • HIV Infections / pathology*
  • HIV Infections / virology
  • HIV-1 / growth & development
  • HIV-1 / immunology
  • HIV-1 / pathogenicity*
  • Heterocyclic Compounds, 3-Ring
  • Heterocyclic Compounds, 4 or More Rings / therapeutic use
  • Humans
  • Neutralization Tests
  • Piperazines
  • Pyridones
  • RNA, Viral / blood
  • RNA, Viral / immunology
  • SARS-CoV-2 / immunology
  • Tenofovir / analogs & derivatives
  • Treatment Failure

Substances

  • Amides
  • COVID-19 Vaccines
  • Heterocyclic Compounds, 3-Ring
  • Heterocyclic Compounds, 4 or More Rings
  • Piperazines
  • Pyridones
  • RNA, Viral
  • bictegravir
  • Tenofovir
  • tenofovir alafenamide
  • Emtricitabine
  • Adenine
  • BNT162 Vaccine
  • Alanine